BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910
BI-1910 is now the second of the company’s anti-tumour necrosis factor receptor 2 programmes to enter clinical development
Read More
Tag: BI-1910
- UKHSA and ICL confirm variant which plays key role in global surge of Strep A infections
- Study reveals heart failure device could monitor patients and prevent hospitalisation
- MIT’s new MRI brain light-detecting technique could support brain cell studies
- PharmaTimes MSEA and NIEA awards are open for entry
- BBSRC invests £48m in Babraham Institute to advance lifelong health research
